C₂N Diagnostics is excited to announce a significant funding milestone, having raised $10,000,000 to accelerate our mission of delivering Clarity Through Innovation™ in the field of neurological health. This infusion of capital marks a key step forward in our commitment to develop and expand mechanism-based therapeutic discovery and diagnostic solutions that aim to prevent or halt the progression of human neurological disorders. Our innovative approach centers on leveraging advanced technology and research to create accessible, cost-effective, and highly accurate blood tests that improve patient care and allow for proactive brain health monitoring.
At the heart of our clinical advancements is our lead commercial product, PrecivityAD™, a mass spectrometry-based blood test performed in our CLIA-certified laboratory. Although PrecivityAD™ itself does not diagnose Alzheimer’s disease—with diagnosis remaining the purview of health care providers—the test plays a crucial role as an evaluation tool that predicts the presence of brain amyloid plaques, correlating with PET scan results. Recognized for its potential, PrecivityAD™ received a Breakthrough Device Designation from the U.S. Food and Drug Administration in 2019 and subsequently achieved the CE Mark in the European Union, affirming its value in modern diagnostic practice.
The new funds will bolster our efforts to enhance the technology behind PrecivityAD™, expand our operational capabilities, and pave the way for additional innovations in both diagnostic and therapeutic arenas. We are committed to driving forward transformative changes in neurological care, ensuring that clinicians have the robust tools they need to make informed decisions for their patients. For more detailed information about our work and future developments, please visit www.C2N.com.
